Human monoclonal antibodies can act as biological substitute for chemical antibiotics

In the course of a new and groundbreaking study, led by Dr, Natalia Freund and the doctoral candidate Avia Waston at the Sackler Medical Faculty, the research group succeeded in isolating monoclonal antibodies, which hindered the growth of tuberculosis germs in laboratory mice.

The antibodies were isolated from a patient who had succumbed to active tuberculosis disease but had since recovered. This is, in fact, the first time in history that researchers have managed to develop a "biological antibiotic" and demonstrate that human monoclonal antibodies can act as a substitute for the traditional chemical antibiotics and protect mice from a pathogenic bacterial challenge.

The study was carried out in a collaboration with two additional laboratories from the US and China and was published in the prestigious scientific journal Nature Communications.

For the last century, antibiotics have served as the main treatment against germs, being both efficient and cheap. Antibiotics are chemical agents, which are designed to block and destroy specific cells, such as microbial cells.

However, since some biological mechanisms are common to both human and microbial cells, the range of antibiotics that can safely be used without harming the patient is limited. For example, cell wall components of many strains of microbes are common to human cells; therefore, any damage caused to the microbial cell walls can lead to extensive damage to body systems.

Furthermore, in recent years the number of microbial strains that are antibiotic-resistant is on the increase, which presents new challenges of how to defend the body from microbes in the post-antibiotic era.

For these reasons, Dr. Natalia Freund and her laboratory team have spent the recent years searching for a biological substitute for known antibiotics. Antibodies are proteins that are produced naturally by our immune response following infection or a vaccine.

They harbor many advantages such as specificity, stability, and safety. For these reasons, today, antibodies are in widespread use in the clinic for the treatment of cancer, autoimmune diseases, and viral infections such as COVID-19.

The research team chose Tuberculosis, which is caused by infection of the bacilli Mycobacterium tuberculosis, as a test model, and were successful, for the first time ever, in devising an effective treatment on the basis of anti-bacterial antibodies naturally developed during infection.

Another reason for the choice of tuberculosis is, that although the vaccine against tuberculosis was developed already 100 years ago, and is based on the attenuated bacillus bovis (BCG) strain, it is not effective in adults and does not prevent infection.

In addition, in recent years, more and more varieties of diseases have developed that are resistant to the only treatment that is currently available, namely, treatment with antibiotics. Since tuberculosis germs are very infectious, transferred in the air, and detrimental to the lungs, the spread of resistant strains of tuberculosis that modern medicine cannot combat is a real danger.

Currently, approximately one-quarter of the world's population is infected by tuberculosis, with the rates of drug-resistant strains peaking to as high as 40% in some countries. In Israel, there are about 200 active tuberculosis cases per year.

According to Dr. Natalia Freund, "Antibiotics are highly efficacious and cost-effective, and therefore for the last years have been our only weapon against bacterial infections. Unfortunately, antibiotics become less and less effective, and in the main cases of drug-resistance physicians are empty-handed in finding an appropriate treatment for their patients. Therefore, new ways to kill bacteria are urgently needed. Advances in biological medicine have enabled us to rout the germs in new ways that are not based solely on antibiotics, and therefore allow a solution to the challenge posed by resistant germs. Our study is an initial proof of concept of employing monoclonal antibodies (derived from single cells) as an effective therapy in combating bacterial pathogens," stresses Dr. Freund.

It should be noted that owing to the size and complexity of the tuberculosis bacillus, isolation of monoclonal antibodies to it has been extremely challenging. But now, the researchers in Dr, Freund's laboratory have succeeded in pinpointing a phosphate pump protein on the bacillus cell wall, which supplies energy to the bacterium and is highly specific and conserved to all tuberculosis strains.

The two types of antibodies the researchers have isolated, which block the action of the pump, inhibit the bacteria growth, and reduced the bacterial levels by 50% in mice as compared with mice that were not treated with antibodies.

Furthermore, these antibodies have been found to be active against three different strains of the tuberculosis bacillus; and seeing that the antibodies are directed against the phosphorus pump, which is common to all strains of this bacillus, it is expected that the vaccine will be effective against many other strains that were not investigated, including those that are resistant to antibiotics.

Presently, in view of the success of the study, Dr. Freund's laboratory is investigating the possibility of extending the "biological" substitute for antibiotics to include other diseases.

The model that has proven successful in this study will enable us to extend our future work to include other diseases such as pneumonia and staphylococcus infections."

Dr, Natalia Freund, Tel Aviv University

Journal reference:

Watson, A., et al. (2021) Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis. Nature Communications.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
You might also like...
Scale Biosciences Continues Commercial Expansion with Introduction of New and Differentiated Single Cell Methylation and Single Cell RNA Sequencing Solutions